Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM), via its subsidiary Cana Laboratories, signed a five-year contract manufacturing agreement with Pharmex for three dermatological products.
The deal covers approximately 2.86 million units, enhances utilization of Cana’s EU-GMP, EMA-certified facility, and targets higher-margin, recurring contract manufacturing revenue.
Positive
- Five-year contract to manufacture approximately 2.86 million units
- Improves utilization of Cana’s EU-GMP, EMA-certified manufacturing facility
- Company aims to strengthen recurring revenue from higher-margin contract manufacturing
- Supports Cosmos Health’s position as a contract manufacturer in pharmaceuticals
Negative
- None.
News Market Reaction – COSM
In the Jun 17 session, COSM declined 3.24%, reflecting a moderate negative market reaction. Argus tracked a peak move of +16.0% during that session. Argus tracked a trough of -22.3% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 15 | U.S. portfolio update | Positive | +14.2% | Projected U.S. 18 Series revenue over $22.7M with ~$17.0M gross profit. |
| Jun 12 | Contract manufacturing | Positive | +1.6% | Cana Laboratories received 253,657-unit manufacturing orders from Nassington and Verisfield. |
| Jun 12 | Brand sales update | Positive | +1.6% | Reported $1.5M+ annualized C-Scrub/C-Sept sales with >70% margins and EU growth targets. |
| Jun 11 | Nasdaq extension | Neutral | -9.7% | 180-day extension to Dec 7, 2026 to regain $1.00 bid price compliance. |
| Jun 10 | Large CM agreement | Positive | +2.1% | Three-year Verisfield deal for 3.9M VASCLOR GEST progesterone pessary units. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent crypto-tag news for COSM has generally seen positive alignment between favorable operational updates and share price moves, with one compliance-related update coinciding with a selloff.
Over the past week, COSM’s crypto-tag news flow has focused on growth initiatives and listings compliance. Contract manufacturing wins, such as the 3.9 million-unit VASCLOR GEST agreement, and updates on U.S. nutraceuticals with projected revenue over $22.7M have supported modest positive price reactions. In contrast, the Nasdaq extension to meet the $1.00 bid price by December 7, 2026 coincided with a negative move, highlighting sensitivity to listing-risk headlines.
Key Terms
eu-gmp-licensed regulatory
ema-certified regulatory
cutaneous solution medical
dermocosmetics medical
contract manufacturing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories S.A. ("Cana"), it has entered into a five-year contract manufacturing agreement with Pharmex S.A. ("Pharmex") to produce three pharmaceutical products.
Under the agreement, Cana will manufacture the following products for Pharmex at its EU-GMP-licensed, EMA-certified facility, with combined volumes of approximately 2.86 million units over the five-year term.
| Product | Active Ingredient | Pharmaceutical Form | Annual Units | Five-Year Total |
| BETAFUSIN® | Betamethasone, Fusidic Acid | Cream | 450,000 | 2,250,000 |
| BOTAFEX® | Minoxidil | Cutaneous Solution | 65,000 | 325,000 |
| BUDESODERM® | Budesonide | Cream / Cutaneous Solution | 57,000 | 285,000 |
| Total | 572,000 | 2,860,000 | ||
The agreement reinforces Cosmos Health's role as a contract manufacturer of pharmaceutical products and supports higher utilization of its EU manufacturing capacity. By leveraging Cana's licensed production capabilities, the Company aims to deepen its long-term manufacturing partnerships and strengthen recurring revenue from its higher-margin contract manufacturing activities.
Founded in 1981, Pharmex is a Greek pharmaceutical company with over 40 years in medicinal products and dermocosmetics. It develops and produces its own products and serves as the exclusive local distributor for international partners. Pharmex products are available in more than 20 countries across Europe, the Middle East, Asia, Africa and Latin America.
Greg Siokas, CEO of Cosmos Health, stated: "This five-year agreement with Pharmex reflects the strength of our manufacturing platform and the trust that pharmaceutical partners place in Cana Laboratories. Contract manufacturing is an important pillar of our vertically integrated model, allowing us to maximize the value of our EU-licensed facilities while building stable, long-term relationships. We look forward to delivering for Pharmex and to expanding these partnerships over time.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
